ClinicalTrials.gg
Enrolling by invitationNCT07867184Updated Oct 23, 2026

Firefighter's Longitudinal Airway and Respiratory Exposome/Multiome Study (FLARES)

An observational study in Anosmia, Chronic Obstructive Pulmonary Disease and Hyposmia, sponsored by National Institute of Allergy and Infectious Diseases (NIAID). Enrolling by invitation at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-23.

Sponsored by National Institute of Allergy and Infectious Diseases (NIAID) · Observational

Updated Oct 23, 2026Start date movedNewly registeredGo to Updates ↓
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
350
Ages
18 Years to 65 Years
Sex
All
01

Study summary

Background:

Exposure to smoke increases the risk of many diseases. People can be exposed to dangerous levels of smoke during wildfires. Also, smoke from fires that burn manmade materials may contain toxic chemicals. Researchers want to know more about how breathing smoke affects a person s airways (nose, sinuses, lungs) and immune system.

Objective:

To learn how exposure to smoke over time affects the health of people who work as firefighters.

Eligibility:

Healthy, nonsmoking people aged 18 to 65 years who work as firefighters. Some people older than 65 may also be included.

Design:

Participants will have study visits about every 6 months for up to 10 years. They will also have visits after a smoke exposure event. Some visits may be by telehealth. Each visit will include some or all of the following:

Imaging scans of the sinuses or chest.

Sample collection. These will include blood, nasal fluids, a skin swab, urine, and fluid coughed up from the lungs.

Lung function test. Participants will blow air into a machine that measures the volume moving in and out of their lungs.

Particles in exhaled air (PExA). Participants will breathe into a device that collects particles.

Heart function test.

Smell test. Participants will identify odors on scratch-and-sniff cards.

Wearable air monitors. Participants may be asked to wear a device that measures particles and chemicals in the air around them for 1 to 20 days.

International Public Safety Data Institute (IPSDI) reports. Participants will provide copies of these fire suppression event reports, if they are available.

Participants who have exams of the airways as part of their routine health care may have extra tissue samples collected for research.

Read the detailed description

Study Description:

This observational natural history study (FLARES) will define the acute and longterm airway, respiratory and immune consequences of anthropogenic smoke exposures that arise from urban and wildland urban interface (WUI) fires. Given their disproportionate exposure, firefighters will be used as a model. The protocol integrates (1) standardized clinical phenotyping, (2) detailed exposure assessment, and (3) multi-omic profiling to enable evidence-based management of smoke- and pollutant-related respiratory impairment.

FLARES will enroll firefighter recruits and active-duty firefighters. Firefighters will be followed longitudinally with twice annual visits to the NIH Clinical Center (NIH CC) and will undergo event-driven evaluations including paired pre- and postexposure assessments around planned fire exposures (eg, live fire simulations) and assessments following unplanned exposures. Systematic evaluation of the upper and lower airways will be coupled with an exposure-informed biorepository of biospecimens - blood, nasal lining fluid, particulates exhaled from deep airways and urine- for multi-omic and exposome analyses to elucidate molecular pathways of smoke- and chemical -related injury. Assessments will include sinus and chest imaging (baseline and 3-year CT with interval magnetic resonance imaging [MRI]), pulmonary function testing (PFT), and detailed exposure questionnaires. Pre/post exposure comparisons and longitudinal trajectories of firefighters will be used to identify early biomarkers, multi-omic trajectories, and clinical indices of perturbed respiratory immunity and sinopulmonary disease in relation to exposure characteristics (eg, frequency, duration, intensity, and fire type), including the growing burden of anthropogenic smoke exposures in the context of climate change.

Objectives:

Primary Objective: Assess changes in multi-omic signatures within airway epithelium/fluids, peripheral blood, and/or urine following anthropogenic smoke exposure.

Secondary Objective: Determine development or progression of upper and/or lower airway disease following anthropogenic smoke exposure at a 3-year interval.

Tertiary Objective: Assess multi-site exposome shifts following anthropogenic smoke exposure.

Exploratory Objectives:

  • Perform power calculations for untargeted metabolomic signatures using data from pilot of metabolomic pathway assessment of sigmaOH-fluorenes and sigmaOHphenanthrenes pre and post live fire simulator.
  • Assess multi-omic shifts following anthropogenic smoke exposure with standard fire department exposure collection data (eg, nature of biofuel, ambient conditions, personal protective equipment use and condition, decontamination practices).
  • Assess organ-specific blood biomarkers on basis of omics level analysis (eg, assess markers of end-neurologic damage in the event of metabolomics pathways suggestive of neurotoxic exposures such as lead or mercury).

Endpoints:

Primary Endpoints:

Fold differences in methylation, transcription, proteomic and/or metabolic pathways:

  • Initial pilot of metabolomic data will include pathway assessment of sigmaOHfluorenes and sigmaOH-phenanthrenes pre and post live fire simulator.
  • Comparing baseline to acute and subacute phases of anthropogenic smoke exposures (eg, firefighter specific monitoring of either planned or unplanned smoke exposure) relative to preceding baseline.
  • Comparing longitudinal changes within individual firefighters relative to time in service.

Primary endpoints may be assessed in context of acute exposures: 0-14 days after defined smoke exposure episode, subacute (15-90 days) post exposure, and chronic (repeated and/or > 90 days post exposure).

Secondary Endpoints: 3-year incidence of participant-reported symptoms corroborated by objective physiologic or inflammatory changes.

1 or more domains identified as meeting at least 1 subjective measure AND at least

1 corresponding objective measure (eg, Chronic Airway Assessment

Test [CAAT] >= 8 AND fractional exhaled nitric oxide [FeNO] > 50 ppb).

Tertiary Endpoint: Direct or estimated smoke chemical levels on wearable, under uniform monitors relative to neutral-location controls (eg, fire station or home) and post-exposure urine versus pre-exposure urine.

Exploratory Endpoints:

  • Power calculation for untargeted metabolomics experiments using pilot of metabolomic pathway assessment of sigmaOH-fluorenes and sigmaOHphenanthrenes pre and post live fire simulator.
  • Fold differences in methylation, transcription, proteomic and/or metabolic pathways in linear mixed-effects models adjusted for individual aspects of standard International Public Safety Data Institute (IPSDI) Exposure Tracker firefighter reporting systems.
  • Direct or estimated smoke chemical levels on wearable, under uniform monitors relative to neutral-location controls (eg, fire station or home) and post-exposure urine vs. pre-exposure in linear mixed-effects models adjusted for individual aspects of standard IPSDI Exposure Tracker firefighter reporting systems.
  • Comparing relative baselines of fire na(SqrRoot) ve recruits to recruits with prior exposure during standard firefighter academy training.
  • Serum levels of markers indicating end organ damage downstream of identified toxins with established organ-specific effect (eg, neurofilament light chain levels in the event of high lead and mercury levels).
02

Conditions studied

  • Anosmia
  • Chronic Obstructive Pulmonary Disease
  • Hyposmia
  • Chronic Rhinosinusitis
  • Asthma

Keywords

  • Firefighter
  • Respiratory
  • Smoke
  • Urban
  • Fire
  • Natural History
03

In context

Anosmia

120 studies on the registry are indexed under Anosmia; 39 are open to participants now.

This study's planned enrollment of 350 is above the median of 218 across 33 observational studies indexed under Anosmia.

Browse Anosmia studies →

Lead sponsor

National Institute of Allergy and Infectious Diseases (NIAID) is the lead sponsor of 2,445 studies on the registry; 182 are open to participants now.

Of its 402 completed or terminated interventional studies of FDA-regulated products, 300 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Healthy firefighter cadets, recruits and active-duty firefighters aged 18 to 65 without history of recreational smoke exposure who are employed within the Maryland, Virginia, and the District of Columbia area.

Eligibility criteria

  • INCLUSION CRITERIA:

To be eligible to participate in this study, an individual must meet all of the following criteria:

  1. Stated willingness to comply with all study procedures and availability for the duration of the study.
  2. Aged 18 to 65 at time of enrollment. Firefighters over the age of 65 may be enrolled per investigator discretion.
  3. In good general health as evidenced by medical history.
  4. Have or are willing to obtain a non-NIH primary physician who will manage all health conditions and be responsive for emergency medical treatment, if required.
  5. Able to provide informed consent.
  6. Willing to allow biological samples and data to be stored for future research.
  7. Have permission of active-duty command to participate in study.
  8. Are an active-duty veteran or recruit firefighter eligible to participate in planned or unplanned firefighting scenarios.

EXCLUSION CRITERIA:

An individual who meets any of the following criteria will be excluded from participation in this study:

  1. Current use of tobacco, marijuana, vaping/e-cigarette or any illicit inhaled, ingested, or injected drugs within 1 year of enrollment.
  2. Pregnancy or lactation.
  3. Treatment with an investigational drug/intervention or immunosuppressive/immunomodulatory medications within 2 years of enrollment.
  4. Current smoker, or tobacco use within 1 year of enrollment or greater than 5 pack-years cumulatively.
  5. Conditions detailed as disqualifying under NFPA Form 1582 pertaining to 1) nose, oropharynx, trachea, and larynx and 2) lung and chest wall pathologies at time of enrollment.
  6. Known inborn error of immunity as cited by the most recent classification of the International Union of Immunological Societies.
  7. Malignancy within 5 years.
  8. Presence of condition(s) that, in the judgment of the investigator or the referring physician, may put the participant at undue risk or make them unsuitable for participation

    in the study.

    Participants will be selected in an equitable manner from the available pool of potentially eligible individuals, without regard to factors such as sex, race, ethnicity, socioeconomic status, etc, except for age, as described below. We note that, given their non-volunteer (ie salaried) status, active-duty firefighters and recruits are screened by NFPA Form 1582 for medical conditions precluding active firefighting duties, which is inclusive of above conditions with the exception of known inborn error of immunity.

    Co-enrollment guidelines: Co-enrollment in other trials is restricted, other than enrollment on observational studies. Consideration for co-enrollment in trials evaluating the use of a licensed medication will require the approval of the principal investigator. Study staff should be notified of co-enrollment on any other protocol.

    Exclusion of Special Populations:

    -Adults Over the Age of 65

    Federal firefighters have a maximum retirement age of 57 years; although there are local departments with individuals over this age. Firefighters over the age of 65 at enrollment who meet all other eligibility criteria will require special permission from investigators to participate in this study. Exceptions will be made on a case-by-case basis to ensure that age-matched cases do not skew disproportionately to an older population.

    -Adults Who Lack, or Lose, Decision-Making Capacity to Consent to Research Participation

    Given the known dangers associated with firefighting, it would be unethical to include individuals who lack decision-making capacity to consent.

    -Exclusion During Pregnancy

    Women who are/become pregnant will be excluded from the study while pregnant and/or lactating given condition specific physiology that may confound the objectives of the study. In the event of pregnancy in a study participant, the participant will temporarily pause all study related activities. Participants may resume study activities 4 weeks after the conclusion of the pregnancy or cessation of lactation.

    -Children

    Children will be excluded from this study given the age minimums to attend firefighting academies.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
350 participants (estimated)

Groups and cohorts

  • Firefighters

    Healthy firefighter cadets, recruits and active-duty firefighters aged 18 to 65 without history of recreational smoke exposure who are employed within the Maryland, Virginia, and the District of Columbia area.

06

What researchers measure

Primary outcomes

  1. Fold differences in methylation, transcription, proteomic and/or metabolic pathways:1. After defined smoke exposure episode 2. Subacute post exposure 3. Chronic (repeated and/or > 90 days post exposure

    Assess changes in multi-omic signatures within airway epithelium/fluids, peripheral blood, and/or urine following anthropogenic smoke exposure

    Time frame: 1. 0-14 days 2. 15-90 days 3. > 90 days

Secondary outcomes

  1. Incidence of participant-reported symptoms corroborated by objective physiologic or inflammatory changes. 1 or more domains identified as meeting at least 1 subjective measure and at least 1 corresponding objective measure, eg, CAAT > 8 AND F...

    Determine development or progression of upper and/or lower airway disease following anthropogenic smoke exposure at a 3-year interval

    Time frame: 3 year interval

07

Study locations

1 site
  • National Institutes of Health Clinical Center
    Bethesda, Maryland 20892, United States
08

References and documents

Individual participant data

Plan to share: Yes — Raw de-identified data will be shared per NIH Data Sharing Policy and publication requirements.@@@@@@

Supporting information: Study protocol, Analytic code

Time frame: Exact time frame is unknown. Will be completed per NIH Data Sharing Policy and publication requirements.@@@@@@

Access criteria: Per PI discretion and repository requirements.

09

Updates

10 registry updates since Sep 25, 2026
Start date
Oct 14, 2026→Oct 28, 2026
moved 9 times, Oct 13, 2026 – Oct 23, 2026
Registered
First appeared on the registry
Oct 9, 2026
Show all 10 updates
  1. Oct 23, 2026
    Start date Oct 27, 2026→Oct 28, 2026
  2. Oct 22, 2026
    Start date Oct 26, 2026→Oct 27, 2026
  3. Oct 21, 2026
    Start date Oct 25, 2026→Oct 26, 2026
  4. Oct 20, 2026
    Start date Oct 22, 2026→Oct 25, 2026
  5. Oct 19, 2026
    Start date Oct 21, 2026→Oct 22, 2026
  6. Oct 16, 2026
    Start date Oct 20, 2026→Oct 21, 2026
  7. Oct 15, 2026
    Start date Oct 19, 2026→Oct 20, 2026
  8. Oct 14, 2026
    Start date Oct 18, 2026→Oct 19, 2026
    + 1 other change: identifiers
  9. Oct 13, 2026
    Start date Oct 14, 2026→Oct 18, 2026
    + 1 other change: description
  10. Oct 9, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07867184
Responsible party
Sponsor
First posted
Oct 9, 2026
Start date
Oct 28, 2026 (estimated)
Primary completion
Oct 31, 2031 (estimated)
Completion
Oct 31, 2036 (estimated)
Last update
Oct 23, 2026

Study contacts

Danielle C Flood, M.D.
principal investigator · National Institute of Allergy and Infectious Diseases (NIAID)

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion